Clinical Trials | April 16, 2024
Novartis reports data from trial of IgA nephropathy treatment
IgAN is a heterogeneous, progressive, rare kidney disease and is a major cause of chronic kidney disease worldwide
IgAN is a heterogeneous, progressive, rare kidney disease and is a major cause of chronic kidney disease worldwide
Global Phase-3 study initiation expected in the second half of 2024
Ajovy confirms efficacy in new Phase 3 data significantly reducing the number of migraine days per month
A significant proportion of healthcare professionals still tend to favor branded drugs
Enhertu now has five approved indications with the latest in HER2-expressing (IHC 3+) metastatic cancers
First and only immunotherapy to demonstrate survival benefit in this setting in a global Phase III trial
TriClip offers a remarkably safe, minimally invasive treatment option for patients in need of tricuspid valve repair but who are unable to withstand surgery
Reconfirms a relative bioavailability of 65 percent and significant savings when using DL-methionine
Application based on results from the TROPION-Breast01 Phase III trial
The FDA assigned a Prescription Drug User Fee Act (PDUFA) goal date of June 21, 2024
Subscribe To Our Newsletter & Stay Updated
